2-phenoxybutanal | 92016-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-phenoxybutanal
• 英文别名: 2-Phenoxy-butyraldehyd；Butanal, 2-phenoxy-
• CAS: 92016-54-1
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: PJNMCGWKYLOSEE-UHFFFAOYSA-N

物化性质

• 沸点：
  70-72 °C(Press: 7 Torr)
• 密度：
  1.022±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-phenoxybutanal 在 Amberlyst 15 作用下， 以 苯 为溶剂， 以96%的产率得到2-乙基苯并呋喃
  参考文献：
  名称：

  Efficient Cyclization of 2‐Phenoxyalkanals to 2‐Alkylbenzo[b]furans

  摘要：

  A new and efficient route to 2-alkylbenzo[b]furans via acid-catalyzed cyclization of 2-phenoxyalkanals under mild conditions over amberlyst-15 resin has been described.

  DOI：

  10.1080/00397910500182747
• 作为产物：
  描述：

  2-Phenoxy-butanol-(1) 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-phenoxybutanal
  参考文献：
  名称：

  手性的对映选择性合成的β-芳氧基的醇通过α-芳氧基醛的不对称氢化经由动态动力学拆分

  摘要：

  Abstractmagnified imageA catalytic enantioselective hydrogenation of racemic α‐aryloxy aldehydes via dynamic kinetic resolution has been developed by using (diamine)(spirodiphosphine)ruthenium(II) chloride [RuCl2(SDPs)(diamine)] catalysts. Employing this new reaction system a variety of optically active β‐aryloxy primary alcohols were synthesized in high yields and moderate to good enantioselectivities.

  DOI：

  10.1002/adsc.200800634

文献信息

• Hydronopol derivatives as agonists on human ORL1 receptors
  申请人：Mentzel Matthias

  公开号：US20050131004A1

  公开（公告）日：2005-06-16

  The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

  本发明涉及一组氢诺普尔衍生物，它们是人ORL1（痛敏素）受体的激动剂。本发明还涉及这些化合物的制备方法，以及含有至少一种这些新型氢诺普尔衍生物作为活性成分的药理活性量的药物组合物，以及这些药物组合物用于治疗涉及ORL1受体的疾病的使用。本发明涉及通式（1）的化合物，其中符号的含义如说明书中所述。
• Benzoheterocyclic derivatives
  申请人：——

  公开号：US20020049194A1

  公开（公告）日：2002-04-25

  A benzoheterocyclic derivative of the following formula [1]: 1 and pharmaceutically acceptable salts thereof, which show excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as a vasopressin antagonist, vasopressin agonist or oxytocin antagonist.

  以下式子所示的苯并杂环衍生物[1]及其药学上可接受的盐，展示出优异的抗加压素活性、加压素激动活性和催产素拮抗活性，可用作加压素拮抗剂、加压素激动剂或催产素拮抗剂。
• Therapeutic agents
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0266979A2

  公开（公告）日：1988-05-11

  The invention concerns novel therapeutic agents containing a (Z)-(2-alkoxyalkyl- or 2-aryloxyalkyl-4-phenyl-1,3-­dioxan-5-yl)alkenoic acid, or a related tetrazole derivative, which antagonises one or more of the actions of thromboxane A₂, together with a compound which inhibits the synthesis of thromboxane A₂. The compositions are useful as medicines in treating a variety of diseases or medical conditions in which thromboxane A₂ and/or other prostanoid contractile substances are involved.

  本发明涉及含有(Z)-(2-烷氧基烷基-或 2-芳氧基烷基-4-苯基-1,3-二氧杂环戊-5-基)烯酸或相关四唑衍生物的新型治疗剂，该治疗剂与抑制血栓素 A₂合成的化合物一起，可拮抗血栓素 A₂的一种或多种作用。 这些组合物可作为药物用于治疗涉及血栓素 A₂和/或其他类固醇收缩物质的多种疾病或病症。
• Phenoxypropyl derivatives
  申请人：FUJIREBIO KABUSHIKI KAISHA

  公开号：EP0318036A2

  公开（公告）日：1989-05-31

  A phenoxypropyl derivative represented by the following formula wherein A represents a formyl group, a pro­tected formyl group, a hydroxymethyl group, a protected hydroxymethyl group, or a halomethyl group, and Z represents a halogen atom, an amino group, a phthalimide group or a group of the formula in which n is 0, 1 or 2.

  下式所代表的苯氧基丙基衍生物 其中 A 代表甲酰基、受保护甲酰基、羟甲基、受保护羟甲基或卤甲基，Z 代表卤素原子、氨基、邻苯二甲酰亚胺基团或下式中的基团 其中 n 为 0、1 或 2。
• Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0531812A1

  公开（公告）日：1993-03-17

  A novel Maillard reaction inhibitor containing at least one compound represented by formula (1) and the salts thereof; methods for producing the compounds of formula (1) and the salts thereof; a composition for inhibiting the Maillard reaction in living body comprising at least one compound of formula (1) and the salts thereof; and a use of said compound for preparing a pharmaceutical preparation for inhibiting the Maillard reaction in living body by administration of a compound of formula (1') or a salt thereof are disclosed.

  本发明公开了一种新型马氏反应抑制剂，其中至少含有一种由式（1）代表的化合物及其盐类；生产式（1）化合物及其盐类的方法；一种用于抑制活体内马氏反应的组合物，其中至少含有一种式（1）化合物及其盐类；以及所述化合物的用途，即通过服用式（1'）化合物或其盐类制备用于抑制活体内马氏反应的药物制剂。